ERBB2 and breast carcinoma: At the time of writing, new preliminary data from the TUXEDO-1 trial suggest high intracranial response rates of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases, with a progression free survival of 14 months [6].